163 related articles for article (PubMed ID: 31757841)
1. Preclinical PERCIST and 25% of SUV
Savaikar MA; Whitehead T; Roy S; Strong L; Fettig N; Prmeau T; Luo J; Li S; Wahl RL; Shoghi KI
J Nucl Med; 2020 Jun; 61(6):842-849. PubMed ID: 31757841
[TBL] [Abstract][Full Text] [Related]
2. Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer.
Roy S; Whitehead TD; Li S; Ademuyiwa FO; Wahl RL; Dehdashti F; Shoghi KI
Eur J Nucl Med Mol Imaging; 2022 Jan; 49(2):550-562. PubMed ID: 34328530
[TBL] [Abstract][Full Text] [Related]
3. Repeatability of Quantitative Whole-Body 18F-FDG PET/CT Uptake Measures as Function of Uptake Interval and Lesion Selection in Non-Small Cell Lung Cancer Patients.
Kramer GM; Frings V; Hoetjes N; Hoekstra OS; Smit EF; de Langen AJ; Boellaard R
J Nucl Med; 2016 Sep; 57(9):1343-9. PubMed ID: 27103020
[TBL] [Abstract][Full Text] [Related]
4. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.
Wahl RL; Jacene H; Kasamon Y; Lodge MA
J Nucl Med; 2009 May; 50 Suppl 1(Suppl 1):122S-50S. PubMed ID: 19403881
[TBL] [Abstract][Full Text] [Related]
5. Comparison of prone versus supine 18F-FDG-PET of locally advanced breast cancer: Phantom and preliminary clinical studies.
Williams JM; Rani SD; Li X; Arlinghaus LR; Lee TC; MacDonald LR; Partridge SC; Kang H; Whisenant JG; Abramson RG; Linden HM; Kinahan PE; Yankeelov TE
Med Phys; 2015 Jul; 42(7):3801-13. PubMed ID: 26133582
[TBL] [Abstract][Full Text] [Related]
6. ¹⁸F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy Regimen.
Groheux D; Biard L; Giacchetti S; Teixeira L; Hindié E; Cuvier C; Vercellino L; Merlet P; de Roquancourt A; de Cremoux P; Resche-Rigon M; Espié M
J Nucl Med; 2016 Apr; 57(4):536-43. PubMed ID: 26697967
[TBL] [Abstract][Full Text] [Related]
7. 18F-FDG PET-Derived Tumor Blood Flow Changes After 1 Cycle of Neoadjuvant Chemotherapy Predicts Outcome in Triple-Negative Breast Cancer.
Humbert O; Riedinger JM; Vrigneaud JM; Kanoun S; Dygai-Cochet I; Berriolo-Riedinger A; Toubeau M; Depardon E; Lassere M; Tisserand S; Fumoleau P; Brunotte F; Cochet A
J Nucl Med; 2016 Nov; 57(11):1707-1712. PubMed ID: 27103025
[TBL] [Abstract][Full Text] [Related]
8. Test-Retest Variability in Lesion SUV and Lesion SUR in
Hofheinz F; Apostolova I; Oehme L; Kotzerke J; van den Hoff J
J Nucl Med; 2017 Nov; 58(11):1770-1775. PubMed ID: 28473598
[TBL] [Abstract][Full Text] [Related]
9. Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer.
Tixier F; Le Rest CC; Hatt M; Albarghach N; Pradier O; Metges JP; Corcos L; Visvikis D
J Nucl Med; 2011 Mar; 52(3):369-78. PubMed ID: 21321270
[TBL] [Abstract][Full Text] [Related]
10. Repeatability of 18F-FDG PET/CT in Advanced Non-Small Cell Lung Cancer: Prospective Assessment in 2 Multicenter Trials.
Weber WA; Gatsonis CA; Mozley PD; Hanna LG; Shields AF; Aberle DR; Govindan R; Torigian DA; Karp JS; Yu JQ; Subramaniam RM; Halvorsen RA; Siegel BA; ;
J Nucl Med; 2015 Aug; 56(8):1137-43. PubMed ID: 25908829
[TBL] [Abstract][Full Text] [Related]
11. Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer.
Groheux D; Hindié E; Giacchetti S; Hamy AS; Berger F; Merlet P; de Roquancourt A; de Cremoux P; Marty M; Hatt M; Espié M
Eur J Cancer; 2014 Jul; 50(11):1864-71. PubMed ID: 24841218
[TBL] [Abstract][Full Text] [Related]
12. Deep learning generation of preclinical positron emission tomography (PET) images from low-count PET with task-based performance assessment.
Dutta K; Laforest R; Luo J; Jha AK; Shoghi KI
Med Phys; 2024 Jun; 51(6):4324-4339. PubMed ID: 38710222
[TBL] [Abstract][Full Text] [Related]
13. Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors.
Benz MR; Evilevitch V; Allen-Auerbach MS; Eilber FC; Phelps ME; Czernin J; Weber WA
J Nucl Med; 2008 Jul; 49(7):1038-46. PubMed ID: 18552153
[TBL] [Abstract][Full Text] [Related]
14. SUV
Laffon E; Marthan R
J Nucl Med; 2020 Sep; 61(9):1405-1409. PubMed ID: 31924720
[No Abstract] [Full Text] [Related]
15. Influence of Statistical Fluctuation on Reproducibility and Accuracy of SUVmax and SUVpeak: A Phantom Study.
Akamatsu G; Ikari Y; Nishida H; Nishio T; Ohnishi A; Maebatake A; Sasaki M; Senda M
J Nucl Med Technol; 2015 Sep; 43(3):222-6. PubMed ID: 26271802
[TBL] [Abstract][Full Text] [Related]
16. Quantitative Comparison of Prone and Supine PERCIST Measurements in Breast Cancer.
Whisenant JG; Williams JM; Kang H; Arlinghaus LR; Abramson RG; Abramson VG; Fakhoury K; Chakravarthy AB; Yankeelov TE
Tomography; 2020 Jun; 6(2):170-176. PubMed ID: 32548293
[TBL] [Abstract][Full Text] [Related]
17. GlucoCEST MRI for the Evaluation Response to Chemotherapeutic and Metabolic Treatments in a Murine Triple-Negative Breast Cancer: A Comparison with[
Capozza M; Anemone A; Dhakan C; Della Peruta M; Bracesco M; Zullino S; Villano D; Terreno E; Longo DL; Aime S
Mol Imaging Biol; 2022 Feb; 24(1):126-134. PubMed ID: 34383241
[TBL] [Abstract][Full Text] [Related]
18. Quantitative Evaluation of Therapeutic Response by FDG-PET-CT in Metastatic Breast Cancer.
Goulon D; Necib H; Henaff B; Rousseau C; Carlier T; Kraeber-Bodere F
Front Med (Lausanne); 2016; 3():19. PubMed ID: 27243012
[TBL] [Abstract][Full Text] [Related]
19. Tumor response to neoadjuvant chemotherapy in patients with esophageal cancer assessed with CT and FDG-PET/CT - RECIST 1.1 vs. PERCIST 1.0.
Odawara S; Kitajima K; Katsuura T; Kurahashi Y; Shinohara H; Yamakado K
Eur J Radiol; 2018 Apr; 101():65-71. PubMed ID: 29571803
[TBL] [Abstract][Full Text] [Related]
20. Early prediction of triple negative breast cancer response to cisplatin treatment using diffusion-weighted MRI and
Nguyen-Thu H; Hanaoka H; Nakajima T; Yamaguchi A; Nguyen-Cong T; Kartamihardja AAP; Tsushima Y
Breast Cancer; 2018 May; 25(3):334-342. PubMed ID: 29357023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
